Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-716 in Healthy Adults and Moderate-to-Severe Atopic Dermatitis
NCT07693738Phase 1Recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- May 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing SSGJ-716 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events (AEs) and serious adverse events (SAEs) at 85 days. Started May 2026; status: recruiting.
02
Drugs
SSGJ-716
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07693738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07693738.